0000000000634361

AUTHOR

Gregory Ducrocq

showing 5 related works from this author

Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insight…

2020

Background: The benefits and risks of blood transfusion in patients with acute myocardial infarction who are anemic or who experience bleeding are debated. We sought to study the association between blood transfusion and ischemic outcomes according to haemoglobin nadir and bleeding status in patients with NST-elevation myocardial infarction (NSTEMI).Methods: The TAO trial randomized patients with NSTEMI and coronary angiogram scheduled within 72h to heparin plus eptifibatide versus otamixaban. After exclusion of patients who underwent coronary artery bypass surgery, patients were categorized according to transfusion status considering transfusion as a timevarying covariate. The primary isch…

medicine.medical_specialtyBlood transfusionAnemiamedicine.medical_treatmentpercutaneous coronary intervention.EptifibatideHemorrhage610 Medicine & healthpercurancous coronary intervention030204 cardiovascular system & hematologyOtamixaban11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.invention03 medical and health sciencesCoronary artery bypass surgerychemistry.chemical_compoundPercutaneous Coronary Intervention0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromeNon ST elevation Myocardial Infarction[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industryBlood transfusionPercutaneous coronary interventionAnemiamedicine.disease3. Good healthTreatment OutcomechemistryEptifibatideCardiology and Cardiovascular Medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol \textless70 mg/dL During 5 Years After Ischemic Stroke

2020

Background and Purpose— The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of <70 mg/dL to reduce the risk of cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebral vasculature or aortic arch plaque >4 mm, in a French and Korean population. The follow-up lasted a median of 5.3 years in French patients (similar to the median follow-up time in the SPARCL trial [Stroke Prevention by Aggressive Reduction in Cholesterol Level]) and 2.0 years in Korean patients. Exposure duration to statin is a well-known driver for cardiovascular risk reduction. We report here the TST results …

Malemedicine.medical_specialtyStatinTime Factorsmedicine.drug_class[SDV]Life Sciences [q-bio]Brain IschemiaLDLchemistry.chemical_compoundDrug Delivery SystemsEzetimibeInternal medicinemedicineClinical endpointHumansangiographyMyocardial infarctionStrokeAgedAdvanced and Specialized NursingCerebral infarctionCholesterolbusiness.industryAnticholesteremic Agentsinformed consentcholesterolCholesterol LDLMiddle Agedmedicine.diseaseEzetimibestroke[SDV] Life Sciences [q-bio]aortachemistryNumber needed to treatCardiologyFemaleNeurology (clinical)Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study.

2016

OBJECTIVE To assess the association between early and prolonged beta blocker treatment and mortality after acute myocardial infarction. DESIGN Multicentre prospective cohort study. SETTING Nationwide French registry of Acute ST- and non-STelevation Myocardial Infarction (FAST-MI) (at 223 centres) at the end of 2005. PARTICIPANTS 2679 consecutive patients with acute myocardial infarction and without heart failure or left ventricular dysfunction. MAIN OUTCOME MEASURES Mortality was assessed at 30 days in relation to early use of beta blockers (<= 48 hours of admission), at one year in relation to discharge prescription, and at five years in relation to one year use. RESULTS beta blockers were…

MaleTime FactorsMyocardial Infarction030204 cardiovascular system & hematologyCorrectionsCohort Studies0302 clinical medicineMedicine030212 general & internal medicineMyocardial infarctionProspective StudiesProspective cohort studyHazard ratioGeneral MedicineMiddle AgedMetaanalysisPatient Discharge3. Good healthManagementImpactAcute DiseaseCardiologyFemaleLife Sciences & Biomedicinemedicine.medical_specialtyRegistrySt-Segment-Elevationmedicine.drug_classAdrenergic beta-AntagonistsGuidelines03 medical and health sciencesMedicine General & InternalFast-MiInternal medicineGeneral & Internal Medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyClinical-OutcomesHumansBeta blockerSurvival analysisAgedProportional Hazards ModelsHeart FailureScience & Technologybusiness.industryProportional hazards modelResearchCoronary Care Unitsmedicine.diseaseSurvival AnalysisDiscontinuationLogistic ModelsAdherenceHeart failureTherapybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBMJ (Clinical research ed.)
researchProduct

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.

2020

Background: Percutaneous left atrial appendage closure (LAAC) exposes to the risk of device thrombosis in patients with atrial fibrillation who frequently have a contraindication to full anticoagulation. Thereby, dual antiplatelet therapy (DAPT) is usually preferred. No randomized study has evaluated nonvitamin K antagonist oral anticoagulant after LAAC, and we decided to evaluate the efficacy and safety of reduced doses of rivaroxaban after LAAC. Methods: ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure) is a multicenter, phase IIb study, which randomized 105 patients after successful LAAC to eith…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsAntithrombin IIIAtrial AppendagePilot Projects030204 cardiovascular system & hematologyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanLeft atrialHeart RateInternal medicineAtrial FibrillationMedicineHumansAtrial Appendage030212 general & internal medicineContraindicationBlood CoagulationAgedAppendageAged 80 and overRivaroxabanbusiness.industryDual Anti-Platelet TherapyAtrial fibrillationThrombosisClopidogrelmedicine.diseasePeptide Fragments3. Good healthTreatment OutcomeCardiologyAtrial Function LeftFemaleProthrombinFranceCardiology and Cardiovascular MedicinebusinessBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsPeptide HydrolasesCirculation. Cardiovascular interventions
researchProduct

Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

2019

Gislason, Gunnar H/0000-0002-0548-402X; Malynovsky, Yaroslav V/0000-0002-9118-1104; Bhatt, Deepak L./0000-0002-1278-6245; Nikolaev, Konstantin/0000-0003-4601-6203; Sherwood, Matthew/0000-0002-4305-5883; Chumakova, Galina A/0000-0002-2810-6531; Raffel, Owen C/0000-0001-5470-7050; Leonardi, Sergio/0000-0002-4800-6132; Tse, Hung Fat/0000-0002-9578-7808; Reshetko, Olga/0000-0003-3107-7636; Pereira, Helder/0000-0001-8656-4883; Racca, Vittorio/0000-0002-4465-3789; Podoleanu, Cristian/0000-0001-9987-2519; Ersanli, Murat/0000-0003-1847-3087; Muenzel, Thomas/0000-0001-5503-4150; Sandhu, Manjinder/0000-0003-2538-2079; Taskinen, Marja-Riitta/0000-0002-6229-3588; bastos, jose/0000-0002-9526-3123; Manak…

MaleBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.Cardiac & Cardiovascular SystemsMyocardial InfarctionUNIVERSAL DEFINITION030204 cardiovascular system & hematologyTHERAPYDISEASEchemistry.chemical_compound0302 clinical medicineCardiac and Cardiovascular Systems030212 general & internal medicineMyocardial infarctionProspective Studies1102 Cardiorespiratory Medicine and HaematologyOxygen supplyKardiologiBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.CHOLESTEROLMiddle AgedMI typesCardiologyLDL Cholesterol LipoproteinsFemaleCardiology and Cardiovascular MedicineLife Sciences & Biomedicinemedicine.medical_specialty610ODYSSEY OUTCOMES InvestigatorsAntibodies Monoclonal HumanizedCLASSIFICATION03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansddc:610Alirocumab ; MI types ; Mortality ; PreventionMortalityMETAANALYSISAlirocumabAgedScience & TechnologyTask forceCholesterolbusiness.industryEVOLOCUMABPrevention1103 Clinical SciencesCholesterol LDLmedicine.diseaseEvolocumabchemistryCardiovascular System & HematologyCardiovascular System & CardiologyHuman medicinebusinessAlirocumab
researchProduct